William Blair Downgrades Complete Genomics | GenomeWeb

NEW YORK (GenomeWeb News) – Citing pricing pressures in the whole-genome sequencing space and Complete Genomics' rising operating expenses, investment bank William Blair today downgraded the Mountain View, Calif.-based firm's stock to Market Perform.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.